

# CITATION REPORT

List of articles citing

Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line

DOI: 10.1016/s0192-0561(96)00068-9

International Journal of Immunopharmacology, 1996, 18, 669-75.

**Source:** <https://exaly.com/paper-pdf/27424945/citation-report.pdf>

**Version:** 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
129	Double filtration plasmapheresis maintains normal adhesion molecule levels. <b>1998</b> , 2, 224-7		10
128	Integrin-dependent leukocyte adhesion involves geranylgeranylated protein(s). <b>1999</b> , 274, 33334-40		58
127	Effect of HMG-CoA reductase inhibitors on chronic allograft rejection. <b>1999</b> , 71, S117-21		18
126	Fluvastatin: a review of its use in lipid disorders. <b>1999</b> , 57, 583-606		50
125	Are statins anti-inflammatory?. <b>2000</b> , 1, 161-165		69
124	Pleiotropic effects of statins. <b>2000</b> , 2, 208-17		121
123	Fluvastatin: effects beyond cholesterol lowering. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , <b>2000</b> , 5, 161-75	2.6	38
122	Non-lipid-related effects of statins. <b>2000</b> , 32, 164-76		269
121	The influence of treatment of hypercholesterolemic patients with simvastatin on plasma chemotactic activity and adherence of neutrophils. <b>2000</b> , 75, 85-90		4
120	Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. <b>2000</b> , 20, 61-9		433
119	Tratamiento hipolipemiante en ancianos. <b>2001</b> , 36, 195-209		
118	HMG-CoA reductase inhibitors reduce adhesion of human monocytes to endothelial cells. <b>2001</b> , 289, 838-44		37
117	Stimulation of inflammatory responses in vitro and in vivo by lipophilic HMG-CoA reductase inhibitors. <b>2001</b> , 1, 105-18		103
116	Non-lipid effects of statin on hypercholesterolemic patients established to have coronary artery disease who remained hypercholesterolemic while eating a step-II diet. <b>2001</b> , 12, 305-11		28
115	Effect of fluvastatin on endothelium-dependent brachial artery vasodilation in patients after renal transplantation. <b>2001</b> , 59, 1473-9		30
114	Novel clinical markers of vascular wall inflammation. <b>2001</b> , 89, 763-71		592
113	Effectiveness of statins in acute coronary syndromes. <b>2001</b> , 88, 31F-5F		6

112	Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. <b>2001</b> , 21, 1712-9	1066
111	Tocotrienol is the most effective vitamin E for reducing endothelial expression of adhesion molecules and adhesion to monocytes. <b>2002</b> , 160, 21-30	96
110	Statins and menopause. <b>2002</b> , 62, 2421-31	5
109	Atherosclerosis and cancer: common pathways on the vascular endothelium. <b>2002</b> , 56, 317-24	40
108	Statins as anti-inflammatory agents. <b>2002</b> , 23, 482-6	277
107	Beyond lipid lowering: the role of statins in vascular protection. <b>2002</b> , 86, 5-18	205
106	Effects of lipids on thrombotic mechanisms in atherosclerosis. <b>2002</b> , 86, 239-47	10
105	Inflammation and atherosclerosis. <b>2002</b> , 105, 1135-43	5212
104	Fluvastatin reduces modification of low-density lipoprotein in hyperlipidemic rabbit loaded with oxidative stress. <b>2002</b> , 436, 97-105	14
103	Effects of statins on six-month survival and clinical restenosis frequency after coronary stent deployment. <b>2002</b> , 90, 299-302	15
102	Anti-inflammatory and immunomodulating properties of statins. An additional tool for the therapeutic approach of systemic autoimmune diseases?. <b>2002</b> , 23, 263-77	24
101	Antiinflammatory and immunomodulatory properties of statins. <b>2002</b> , 25, 271-85	54
100	Statins and the role of nitric oxide in chronic heart failure. <b>2003</b> , 8, 99-106	56
99	[Cholesterol-reducing medications-a new therapeutic option for multiple sclerosis? Statins as immunomodulators]. <b>2003</b> , 74, 704-7	0
98	Cerivastatin ameliorates high insulin-enhanced neutrophil-endothelial cell adhesion and endothelial intercellular adhesion molecule-1 expression by inhibiting mitogen-activated protein kinase activation. <b>2003</b> , 17, 380-6	18
97	The lipid and non-lipid effects of statins. <b>2003</b> , 99, 95-112	200
96	Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model. <b>2003</b> , 48, 3272-9	125
95	Anti-inflammatory and immunomodulatory effects of statins. <b>2003</b> , 63, 12-23	229

94	The effect of apheresis on adhesion molecules. <b>2003</b> , 7, 425-30	6
93	Effects of statins on adhesion molecule expression in endothelial cells. <b>2003</b> , 1, 2290-9	27
92	Atherosclerosis: anti-inflammatory and immunomodulatory activities of statins. <b>2003</b> , 2, 332-8	86
91	Probing antiphospholipid-mediated thrombosis: the interplay between anticardiolipin antibodies and endothelial cells. <b>2003</b> , 12, 539-45	42
90	Endothelium-dependent effects of statins. <b>2003</b> , 23, 729-36	329
89	3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect against oxidized low-density lipoprotein-induced endothelial dysfunction. <b>2003</b> , 10, 17-21	34
88	The Pleiotropic Effects of Statins: Relevance to Their Salutary Effects. <b>2004</b> , 163-187	3
87	Effects of Statins on C-Reactive Protein: Are All Statins Similar?. <b>2004</b> , 189-201	
86	Statins, Inflammation, and C-Reactive Protein. <b>2004</b> , 219-232	
85	Global analysis of RNA expression profile in human vascular cells treated with statins. <b>2004</b> , 11, 62-72	59
84	Statins and the Role of Nitric Oxide in Chronic Heart Failure. <b>2004</b> , 187-194	1
83	Actions of Statins on Ox-LDL-Mediated Signaling and Inflammation. <b>2004</b> , 203-218	
82	Pleiotropic Effects of Statins. <b>2004</b> , 39, 239-258	2
81	Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells. <b>2004</b> , 2, 1558-63	108
80	Are statins a treatment option for multiple sclerosis?. <b>2004</b> , 3, 369-71	61
79	Inflammation and atherosclerosis. <b>2004</b> , 6, 131-9	47
78	Regulation of gene expression associated with acute experimental autoimmune encephalomyelitis by Lovastatin. <b>2004</b> , 77, 63-81	71
77	Statins in hypertensive patients: potential explanations for the ASCOT-LLA study results. <b>2004</b> , 64 Suppl 2, 61-7	5

76	Immunologic manipulation for the threatened fetus. <b>2004</b> , 114, 427-34	2
75	Intracellular signaling triggered by antiphospholipid antibodies in platelets and endothelial cells: a pathway to targeted therapies. <b>2004</b> , 114, 467-76	75
74	Vascular effects of diet and statin in hypercholesterolemic patients. <b>2004</b> , 95, 185-91	40
73	Impact of statin treatment on 1-year functional and histologic renal allograft outcome. <b>2005</b> , 80, 332-8	29
72	Molecular Pathogenesis of the Antiphospholipid Syndrome: Toward Novel Therapeutic Targets. <b>2005</b> , 377-391	
71	The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, lovastatin (statin) ameliorates CCK-induced acute pancreatitis in rats. <b>2005</b> , 28, 1394-7	11
70	Fluvastatin in the therapy of acute coronary syndrome: Rationale and design of a multicenter, randomized, double-blind, placebo-controlled trial (The FACS Trial)[ISRCTN81331696]. <b>2005</b> , 6, 4	11
69	Diverse effects of statins on endothelial cells?. <b>2005</b> , 93, 186-188	5
68	Differential effect of LFA703, pravastatin, and fluvastatin on production of IL-18 and expression of ICAM-1 and CD40 in human monocytes. <b>2005</b> , 77, 400-7	25
67	Treatment with simvastatin suppresses the development of experimental abdominal aortic aneurysms in normal and hypercholesterolemic mice. <b>2005</b> , 241, 92-101	131
66	Increased cholesterol deposition, expression of scavenger receptors, and response to chemotactic factors in Abca1-deficient macrophages. <b>2005</b> , 25, 1198-205	84
65	Effects of atorvastatin on reactive hyperemia and inflammatory process in patients with congestive heart failure. <b>2005</b> , 178, 359-63	85
64	Predicting risk and treatment benefit in atherosclerosis: the role of C-reactive protein. <b>2005</b> , 98, 199-206	61
63	Pleiotropic effects of statins. <b>2005</b> , 45, 89-118	1303
62	Pretreatment with simvastatin reduces lung injury related to intestinal ischemia-reperfusion in rats. <b>2006</b> , 102, 225-32	595
61	Simvastatin treatment modifies polymorphonuclear leukocyte function in high-risk individuals: a longitudinal study. <b>2006</b> , 24, 2423-30	28
60	Fluvastatin, HMG-CoA Reductase Inhibitor: Antiatherogenic Profiles Through Its Lipid-Lowering Dependent and -Independent Actions. <b>2006</b> , 18, 284-303	5
59	Statins in the treatment of polycythaemia vera and allied disorders: an antithrombotic and cytoreductive potential?. <b>2006</b> , 30, 1217-25	25

58	Simvastatin inhibits the migration and adhesion of monocytic cells and disorganizes the cytoskeleton of activated endothelial cells. <b>2006</b> , 548, 53-63	23
57	In vivo and in vitro effects of simvastatin on inflammatory markers in pre-dialysis patients. <b>2006</b> , 21, 337-44	44
56	Mechanisms of action of statins in stroke. <b>2007</b> , 11, 273-8	12
55	Evaluation of atorvastatin and simvastatin for treatment of multiple sclerosis. <b>2007</b> , 7, 547-56	22
54	Simvastatin protects against multiple low-dose streptozotocin-induced type 1 diabetes in CD-1 mice and recurrence of disease in nonobese diabetic mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2007</b> , 323, 180-5	4-7 25
53	Lovastatin improves histological and functional outcomes and reduces inflammation after experimental traumatic brain injury. <b>2007</b> , 81, 288-98	89
52	El monocito/macrófago como diana terapéutica en la aterosclerosis. <b>2007</b> , 19, 92-108	1
51	Statins and biomarkers of inflammation. <b>2007</b> , 9, 33-41	52
50	Statin therapy for vascular failure. <b>2007</b> , 21, 281-95	19
49	Possible strategies to protect the preterm brain against the fetal inflammatory response. <b>2001</b> , 86, 18-20	4
48	HMG-CoA reductase inhibitors deplete circulating classical and non-classical monocytes following human heart transplantation. <b>2008</b> , 19, 152-7	16
47	Antiphospholipid antibody syndrome and autoimmune diseases. <b>2008</b> , 22, 53-65, vi	22
46	Pleiotropic vasoprotective effects of statins: the chicken or the egg?. <b>2009</b> , 3, 191-204	8
45	Potential immunologic effects of statins in cancer following transplantation. <b>2009</b> , 58, 461-7	8
44	Update on statin-mediated anti-inflammatory activities in atherosclerosis. <b>2009</b> , 31, 127-42	64
43	Simvastatin reduces secondary brain injury caused by cortical contusion in rats: possible involvement of TLR4/NF-kappaB pathway. <b>2009</b> , 216, 398-406	107
42	Statins for the treatment of antiphospholipid syndrome?. <b>2009</b> , 1173, 736-45	39
41	Long-term statin therapy affects the severity of chronic gastritis. <b>2010</b> , 15, 510-5	19

40	Statins for community-acquired pneumonia: current state of the science. <b>2010</b> , 29, 143-52		37
39	Atherosclerosis induced by chronic inhibition of the synthesis of nitric oxide in moderately hypercholesterolaemic rabbits is suppressed by pitavastatin. <b>2010</b> , 159, 1418-28		15
38	De Gruyter. <b>2010</b> , 34, -		
37	Atorvastatin ameliorates inflammatory hyperalgesia in rat model of monoarticular arthritis. <b>2010</b> , 61, 329-33		24
36	Anti-cytokine strategies for the treatment of cancer-related anorexia and cachexia. <b>2010</b> , 10, 1241-50		29
35	Assessment of IgG antibodies to oxidized LDL in patients with acute coronary syndrome. <b>2011</b> , 20, 730-5		28
34	Pleiotropic role of atorvastatin in regulation of human retinal pigment epithelial cell behaviors in vitro. <b>2011</b> , 93, 842-51		14
33	Atherosclerosis risk in antiphospholipid syndrome. <b>2011</b> , 6, 583-593		
32	A pilot study of the short-term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunction. <b>2011</b> , 153, 655-63		58
31	Effects of immunomodulatory drugs on plasma inflammatory markers in a rabbit model of atherosclerosis. <b>2011</b> , 67, 115-20		6
30	Do statins have a role in reduction/prevention of post-PCI restenosis?. <i>Cardiovascular Therapeutics</i> , <b>2013</b> , 31, 12-26	3.3	18
29	Statin Modulation of Human T-Cell Proliferation, IL-1 $\beta$ and IL-17 Production, and IFN- $\gamma$ Cell Expression: Synergy with Conventional Immunosuppressive Agents. <i>International Journal of Inflammation</i> , <b>2013</b> , 2013, 434586	6.4	26
28	Topical simvastatin improves the pro-angiogenic and pro-osteogenic properties of bioglass putty in the rat calvaria critical-size model. <i>Journal of Oral Implantology</i> , <b>2014</b> , 40, 251-8	1.2	13
27	Repurposing Treatments to Enhance Innate Immunity. Can Statins Improve Neutrophil Functions and Clinical Outcomes in COPD?. <i>Journal of Clinical Medicine</i> , <b>2016</b> , 5,	5.1	28
26	Diet-Modulated Lipoprotein Metabolism and Vascular Inflammation Evaluated by F-fluorodeoxyglucose Positron Emission Tomography. <i>Nutrients</i> , <b>2018</b> , 10,	6.7	1
25	Exploring the In Vivo Anti-Inflammatory Actions of Simvastatin-Loaded Porous Microspheres on Inflamed Tenocytes in a Collagenase-Induced Animal Model of Achilles Tendinitis. <i>International Journal of Molecular Sciences</i> , <b>2018</b> , 19,	6.3	20
24	The Effects of Pitavastatin on Nuclear Factor-Kappa B and ICAM-1 in Human Saphenous Vein Graft Endothelial Culture. <i>Cardiovascular Therapeutics</i> , <b>2019</b> , 2019, 2549432	3.3	2
23	Statins Withdrawal Induces Atherosclerotic Plaque Destabilization in Animal Model-A "Rebound" Stimulation of Inflammation. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , <b>2019</b> , 24, 377-386	2.6	6

22	Transdermal delivery of fluvastatin sodium tailored spanlastic nanovesicles: mitigated Freund's adjuvant-induced rheumatoid arthritis in rats through suppressing p38 MAPK signaling pathway. <i>Drug Delivery</i> , <b>2019</b> , 26, 1140-1154	7	14
21	Primary Prevention of Cardiovascular Diseases and Related Deaths According to Statin Type. <i>International Journal of Environmental Research and Public Health</i> , <b>2020</b> , 17,	4.6	
20	Fluvastatin Induces Apoptosis in Primary and Transformed Mast Cells. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2020</b> , 374, 104-112	4.7	5
19	Regulation of Long Non-Coding RNAs by Statins in Atherosclerosis. <i>Biomolecules</i> , <b>2021</b> , 11,	5.9	0
18	A comparison of the effects of monotherapy with rosuvastatin, atorvastatin or ezetimibe versus combination treatment with rosuvastatin-ezetimibe and atorvastatin-ezetimibe on the integrity of vascular endothelial cells damaged by oxidized cholesterol. <i>PLoS ONE</i> , <b>2021</b> , 16, e0256996	3.7	0
17	Modulation of macrophage function and metabolism. <i>Handbook of Experimental Pharmacology</i> , <b>2005</b> , 665-95	3.2	5
16	Dietary Fat Intake: Promotion of Disease in Carotid Artery Disease: Lipid Lowering Versus Side Effects of Statins. <b>2010</b> , 151-184		1
15	Role of statins in cerebral vasospasm. <i>Acta Neurochirurgica Supplementum</i> , <b>2008</b> , 104, 287-90	1.7	16
14	Fluvastatin suppresses atherosclerotic progression, mediated through its inhibitory effect on endothelial dysfunction, lipid peroxidation, and macrophage deposition. <i>Journal of Cardiovascular Pharmacology</i> , <b>2000</b> , 35, 136-44	3.1	37
13	Treatment of patients with lipid disorders in the primary care setting: new treatment guidelines and their implications. <i>Southern Medical Journal</i> , <b>2003</b> , 96, 266-75	0.6	5
12	Anti-inflammatory effect of fluvastatin on IL-8 production induced by <i>Pseudomonas aeruginosa</i> and <i>Aspergillus fumigatus</i> antigens in cystic fibrosis. <i>PLoS ONE</i> , <b>2011</b> , 6, e22655	3.7	19
11	Amelioration of Renal Inflammation, Endoplasmic Reticulum Stress and Apoptosis Underlies the Protective Effect of Low Dosage of Atorvastatin in Gentamicin-Induced Nephrotoxicity. <i>PLoS ONE</i> , <b>2016</b> , 11, e0164528	3.7	31
10	Pravastatin-induced changes in expression of long non-coding and coding RNAs in endothelial cells. <i>Physiological Reports</i> , <b>2021</b> , 9, e14661	2.6	2
9	Treatment of severe sepsis: where next? Current and future treatment approaches after the introduction of drotrecogin alfa. <i>Vascular Health and Risk Management</i> , <b>2006</b> , 2, 3-18	4.4	8
8	Outcome of rheumatoid arthritis following adjunct statin therapy. <i>Indian Journal of Pharmacology</i> , <b>2015</b> , 47, 605-9	2.5	10
7	Pleiotropic effects of HMG-CoA reductase inhibitors on cells of the vascular wall. <b>2002</b> , 81-98		
6	Cellular effects of HMG-CoA reductase inhibitors on blood cells (monocytes, macrophages, platelets). <b>2002</b> , 55-80		
5	The effect of early treatment by cerivastatin on the serum level of C-reactive protein, interleukin-6, and interleukin-8 in the patients with unstable angina and non-Q-wave myocardial infarction. <b>2003</b> , 45-50		1



4	Statins in the first-line therapy of acute coronary syndrome - similar to aspirin?. <i>Experimental and Clinical Cardiology</i> , <b>2005</b> , 10, 9-16		2
3	Statins as first-line therapy for acute coronary syndrome?. <i>Experimental and Clinical Cardiology</i> , <b>2012</b> , 17, 227-36		9
2	The effect of early treatment by cerivastatin on the serum level of C-reactive protein, interleukin-6, and interleukin-8 in the patients with unstable angina and non-Q-wave myocardial infarction. <i>Molecular and Cellular Biochemistry</i> , <b>2003</b> , 246, 45-50	4.2	11
1	Monocytic Cell Adhesion to Oxidised Ligands: Relevance to Cardiovascular Disease. <b>2022</b> , 10, 3083		0